CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates inside the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services that help clients move from target identification through non-clinical development and product release.

Revenue for 2025 totaled $4.0 billion and was split across three reportable segments: Discovery and Safety Assessment (DSA) at 59.8%, Manufacturing Solutions at 19.1%, and Research Models and Services (RMS) at 21.1%. The company currently runs more than 120 sites across more than 20 countries, giving it a broad geographic footprint to match its broad scientific footprint.

The reported margin metrics, however, do not paint the picture of a business currently extracting high returns from that scale. Net margin is -6.0% and return on equity is -7.7%. A negative ROE alongside negative net margin means the company is consuming equity capital without generating reported profit at this snapshot. That is consistent with a business in restructuring or integration mode rather than one harvesting a deep competitive moat. The integrated portfolio and global site network still provide strategic breadth, but the current financial returns suggest that competitive advantages are not yet translating into bottom-line profitability.

Financial posture

Charles River Laboratories carries a $14.5 billion market capitalization. The trailing price-to-earnings ratio is -62.1, which directly reflects the negative net margin and means the stock cannot be evaluated on a trailing earnings yield basis. The company is currently reporting losses, so investors must rely on forward estimates, revenue multiples, and turnaround prospects rather than trailing EPS.

The other posture signals are also worth noting. ROE is -7.7%, showing that shareholder equity is being eroded by recent losses at the reported level. Beta sits at 1.40, materially above the market baseline of 1.0, so the stock has historically moved with greater volatility than the broader market. Against that backdrop, the current price of $300.47 sits above the 50-day exponential moving average of $282.53, while the RSI of 55.8 is near neutral territory. None of these figures, individually, indicate direction; together they describe a technically mid-range stock with fundamental losses and above-average sensitivity to market swings.

Strategic priorities & outlook

The company’s most recent SEC 10-K filing outlines a near-term agenda built around operational consolidation and portfolio integration rather than aggressive expansion. Management plans to optimize the global footprint by closing or consolidating approximately 12 additional sites over the next two years, with the majority of those actions falling inside the DSA and RMS segments. That kind of footprint reduction is a classic margin-improvement lever and signals that management is focused on taking cost out of the network.

At the same time, Charles River is integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership structure. The stated goal is to become the scientific partner of choice by delivering a comprehensive and integrated portfolio that can accelerate biomedical research and therapeutic innovation. Separately, the company is looking to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

A real recent operational move aligned with that roadmap is the January 2026 acquisition of certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates. The company said the deal supports DSA supply operations and RMS third-party sales, which tightens an important part of the animal-model supply chain while broadening third-party revenue opportunities.

Macro & geopolitical exposure

Because Charles River sits in the Medical – Diagnostics & Research industry, its exposures line up with the broader contract-research and non-clinical development ecosystem rather than with direct consumer healthcare demand. Key macro drivers include biopharmaceutical R&D budgets, small- and mid-cap biotechnology funding, and the regulatory cycle for new drug candidates. Softening venture-capital flows or higher-for-longer interest rates can pressure smaller biotech clients, which in turn can reduce demand for safety assessment and discovery services.

Regulatory exposure is also central. GLP and non-GLP safety studies must meet FDA, EMA, and other national standards, meaning changes in compliance rules or inspection schedules can affect capacity utilization and pricing. The animal-sourcing side of the business adds another layer: import rules, ethical guidelines, and customs or logistics disruptions for non-human primates can ripple into DSA supply operations. With operations in more than 20 countries, currency translation and cross-border labor costs are additional, ongoing factors. None of these are company-specific predictions; they are structural features of the industry classification.

Recent developments

• October 15, 2026 (defenseworld.net): “Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average – Should You Sell?” The headline itself framed a technical milestone and posed the question of whether to take profits, without offering a definitive view.
• October 13, 2026 (businesswire.com): Charles River announced a collaboration with Magellan Stem Cells to advance stem cell and regenerative medicine development. This fits the broader strategy of deepening scientific partnerships and expanding exposure to high-growth therapeutic modalities.
• October 9, 2026 (businesswire.com): Charles River Laboratories scheduled its third-quarter 2026 earnings release and conference call. The release is set for November 4, 2026, before the market open.
• October 7, 2026 (zacks.com): A head-to-head value comparison asked “PGNY or CRL: Which Is the Better Value Stock Right Now?” The article raised a valuation question but, as with any single-article comparison, did not settle it for the broader market.

Earnings behavior & post-earnings drift

Charles River Laboratories has delivered an unusually consistent earnings record over the last eight reported quarters, beating consensus estimates in all eight quarters for a 100% beat rate. The average earnings surprise across those eight reports is 9.3%. That is a strong headline track record, though the stock’s price reaction has not always matched the direction of the beat.

Across the same eight quarters, the average 5-day price move after earnings has been +1.24%, classified as an “up” post-earnings drift. The most recent quarters show how lumpy that drift can be:

• On August 5, 2026, CRL reported actual EPS of $3.02 against an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five sessions.
• On May 7, 2026, actual EPS of $2.06 beat the $1.96 estimate by 5.1%, yet the stock fell 2.23% the next day and dropped 12.42% over the next five sessions.
• On February 18, 2026, actual EPS of $2.39 beat the $2.33 estimate by 2.6%, with the stock rising 3.95% the next day and 6.05% over the next five sessions.
• On November 5, 2025, actual EPS of $2.43 beat the $2.32 estimate by 4.7%, producing a 1.9% next-day gain and a 2.27% five-day gain.

Looking ahead, the next scheduled report is November 4, 2026, before the open, with a consensus EPS estimate of $2.97. The historical beat rate suggests expectations are high, but the May 2026 example shows that a beat alone does not guarantee a positive price reaction if guidance, margins, or macro sentiment shift.

For a deeper dive, readers should examine the full institutional verdict on Charles River Laboratories, including sell-side ratings, forward estimate revisions, and target ranges, to see how professionals are weighing the company’s footprint consolidation against its recent profitability pressure.